Prognostic implication of MYC/BCL2 in patients with diffuse large B-Cell NHL / Dina Alsaeed Mohamed Algamal ; Supervised Thoraya Mohamed Abdelhamid , Ayman Abdelsamie Gaber , Raafat Mohamed Abdelfattah

By:

Dina Alsaeed Mohamed Algamal

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Dina Alsaeed Mohamed Algamal , 2021Description: 226 P . : charts ; 25cmOther title:

الكبيرة المنتشرة B فى ورم غير هودجكن الليمفاوى للخلايا C-MYC/BCL-2الآثار المنذرة والمترتبة على وجود [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical ) Summary: Background: non-Hodgkin lymphoma is the 7th most commonly diagnosed cancer among men and women; diffuse large B-cell lymphoma represents 32% of non-Hodgkin's lymphoma cases. In Egypt, NHL is the 5th most common cancer. Aim: to study the frequency of C-MYC/BCL-2 in adult Diffuse Large B Cell Lymphoma (DLBCL) patients presented to Egyptian National Cancer Institute and Tanta Cancer Center and to classify these patients into GC & ABC according to CD-10, BCL-6 and MUM-1. And to assess the correlation between the presence of these prognostic markers and treatment outcome, overall survival and disease free survival Methods: this is a prospective study that included 100 adult patients with newly diagnosed and pathological confirmed Diffuse Large-B Cell Lymphoma (CD20+) who were treated by R- CHOP regimen presenting to Egyptian National Cancer Institute and Tanta Cancer Center between the period of January 2014 and December 2016 and followed up till January 2019. Detection of CD10, BCL6, MUM1, C-MYC and BCL2 by immunohistochemistry as prognostic markers. The following data were studied: patient's characteristics, treatment outcome and prospective overall Results: Age ranged from 25-68 years (median age was 49 years). Male cases were 52(52%) while female were 48(48%). Most of our patients presented with advanced stage (42% stage III and 25% stage IV) and (45%) of patients had bulky disease. Extra nodal sites were detected in 42% and patients presented with B-symptoms were 59%. The revised IPI showed that 4% had low IPI, 63% had intermediate IPI and 33% had high IPI. Chemotherapy response showed that 78 patients (78%) had CR response. CR response was lower in the double hit group (45%) while there is no difference between germinal center and non- germinal center groups. Only 21 patients were relapsed

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2021.Di.P (Browse shelf(Opens below))		Not for loan		01010110083370000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2021.Di.P (Browse shelf(Opens below))	83370.CD	Not for loan		01020110083370000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical )

Background: non-Hodgkin lymphoma is the 7th most commonly diagnosed cancer among men and women; diffuse large B-cell lymphoma represents 32% of non-Hodgkin's lymphoma cases. In Egypt, NHL is the 5th most common cancer. Aim: to study the frequency of C-MYC/BCL-2 in adult Diffuse Large B Cell Lymphoma (DLBCL) patients presented to Egyptian National Cancer Institute and Tanta Cancer Center and to classify these patients into GC & ABC according to CD-10, BCL-6 and MUM-1. And to assess the correlation between the presence of these prognostic markers and treatment outcome, overall survival and disease free survival Methods: this is a prospective study that included 100 adult patients with newly diagnosed and pathological confirmed Diffuse Large-B Cell Lymphoma (CD20+) who were treated by R- CHOP regimen presenting to Egyptian National Cancer Institute and Tanta Cancer Center between the period of January 2014 and December 2016 and followed up till January 2019. Detection of CD10, BCL6, MUM1, C-MYC and BCL2 by immunohistochemistry as prognostic markers. The following data were studied: patient's characteristics, treatment outcome and prospective overall Results: Age ranged from 25-68 years (median age was 49 years). Male cases were 52(52%) while female were 48(48%). Most of our patients presented with advanced stage (42% stage III and 25% stage IV) and (45%) of patients had bulky disease. Extra nodal sites were detected in 42% and patients presented with B-symptoms were 59%. The revised IPI showed that 4% had low IPI, 63% had intermediate IPI and 33% had high IPI. Chemotherapy response showed that 78 patients (78%) had CR response. CR response was lower in the double hit group (45%) while there is no difference between germinal center and non- germinal center groups. Only 21 patients were relapsed

Issued also as CD

There are no comments on this title.

to post a comment.